Compartir
Título
The European antibody network's practical guide to finding and validating suitable antibodies for research
Autor
Facultad/Centro
Área de conocimiento
Título de la revista
mAbs
Número de la revista
1
Cita Bibliográfica
Roncador, G., Engel, P., Maestre, L., Anderson, A. P., Cordell, J. L., Cragg, M. S., Šerbec, V. Č., Jones, M., Lisnic, V. J., Kremer, L., Li, D., Koch-Nolte, F., Pascual, N., Rodríguez Barbosa, J.-I., Torensma, R., Turley, H., Pulford, K., & Banham, A. H. (2016). The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs, 8(1), 27-36. https://doi.org/10.1080/19420862.2015.1100787
Editorial
Taylor and Francis Group
Fecha
2016
ISSN
1942-0862
Resumen
[EN]Antibodies are widely exploited as research/diagnostic tools and therapeutics. Despite providing exciting research opportunities, the multitude of available antibodies also offers a bewildering array of choice. Importantly, not all companies comply with the highest standards, and thus many reagents fail basic validation tests. The responsibility for antibodies being fit for purpose rests, surprisingly, with their user. This paper condenses the extensive experience of the European Monoclonal Antibody Network to help researchers identify antibodies specific for their target antigen. A stepwise strategy is provided for prioritising antibodies and making informed decisions regarding further essential validation requirements. Web-based antibody validation guides provide practical approaches for testing antibody activity and specificity. We aim to enable researchers with little or no prior experience of antibody characterization to understand how to determine the suitability of their antibody for its intended purpose, enabling both time and cost effective generation of high quality antibody-based data fit for publication.
Materia
Palabras clave
Peer review
SI
ID proyecto
- info:eu-repo/grantAgreement/MINECO/Programa Estatal de I+D+I Orientada a los Retos de la Sociedad/ PI14/00703/ES/ Anticuerpos Anti-CCR9 para Inmunoterapia Antitumoral en Pacientes con Leucemia Linfoblástica Aguda de Inmunofenotipo T (LLAT)
- info:eu-repo/grantAgreement/Junta de Castilla y León/Otro/LE007A10-2/ES/ El papel de la ruta de co-estimulación HVEM/LIGHT como diana terapéutica para la prevención del rechazo
URI
DOI
Versión del editor
Aparece en las colecciones
- Artículos [4694]
Ficheros en el ítem
Tamaño:
655.8
xmlui.dri2xhtml.METS-1.0.size-kilobytes
Formato:
Adobe PDF